TB VACCINE DEVELOPMENT IN NONHUMAN PRIMATE MODEL

非人灵长类动物模型中的结核病疫苗开发

• 批准号: 7957928
• 负责人: JOHN L VANDEBERG
• 金额: $ 39.21万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-06 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7957928
• 关键词: Acquired Immunodeficiency Syndrome; Antibiotics; Antigens; Computer Retrieval of Information on Scientific Projects Database; DNA; DNA Sequence; Development; Disease; Drug Formulations; Encapsulated; Funding; Grant; Heat shock proteins; Immune; Immune response; Institution; Macaca mulatta; Microspheres; Modeling; Mus; Mycobacterium tuberculosis; Patients; Plasmids; Population; Primates; Proteins; Public Health; Research; Research Personnel; Resources; Secondary Immunization; Severity of illness; Source; Testing; Tuberculosis; Tuberculosis Vaccines; United States National Institutes of Health; Vaccines; base; nonhuman primate; prophylactic; research study; resistant strain; response; vaccine development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. More than 2 billion people, one-third of the world's population, are infected with Mycobacterium tuberculosis. Three million people die each year of TB. The public health problem is intensifying as the heavy use of antibiotics, particularly in AIDS patients, is leading to antibiotic resistant strains of M. tuberculosis. Existing vaccines have serious limitations. This project is determining the immunological responses of rhesus monkeys to M. tuberculosis infection, and the pathological development of disease, in more detail than has been done previously. When the immune correlates of TB have been well defined, a formulation of heat shock protein 65 (hsp65) and a plasmid containing the hsp65 DNA sequence will be encapsulated together with an immunostimulatory protein in microspheres, and tested as a vaccine. The rationale is that the plasmid will quickly exit the microspheres, integrate into host DNA, and produce hsp65, which will serve as an immunogen. Later, the hsp65 protein will be slowly released for up to 60 days, serving as antigen for a booster immunization. Based on prior experiments with mice, the vaccine is expected to have prophylactic activity and also to be capable of stimulating a more effective immune response than is normal in people who already are infected with M. tuberculosis, thereby reducing the severity of disease.

这个子项目是众多研究子项目之一